Boston Scientific Corp (BSX)

Currency in USD
62.07
-3.62(-5.51%)
Closed·
62.10+0.03(+0.05%)
·
BSX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
61.9665.97
52 wk Range
59.39109.50
Key Statistics
Prev. Close
65.69
Open
65.8
Day's Range
61.96-65.97
52 wk Range
59.39-109.5
Volume
17.69M
Average Volume (3m)
17.32M
1-Year Change
-39.0873%
Book Value / Share
16.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BSX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
85.94
Upside
+38.45%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Boston Scientific Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corp SWOT Analysis


Market Dominance
Boston Scientific's strategic acquisitions and robust product portfolio solidify its position as a medtech leader, driving impressive revenue growth and market share gains
Financial Prowess
Explore the company's strong financial performance, with double-digit organic growth and healthy profit margins, signaling a positive trajectory for investors
Innovation Pipeline
Delve into Boston Scientific's R&D focus and product innovations, including the Watchman device, which are expanding addressable markets and fueling future growth
Analyst Optimism
Discover why analysts project sustained growth, with price targets ranging from $84 to $135, reflecting confidence in Boston Scientific's market strategy and potential
Read full SWOT analysis

Boston Scientific Corp Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of $0.80 beat estimates by $0.01; revenue of $5.20B exceeded forecast of $5.17B with 11.6% YoY growth
  • Full-year guidance slashed: revenue growth lowered to 7.0%-8.5%, adjusted EPS cut to $3.34-$3.41 amid business headwinds
  • Stock surged 6.53% to $63.41 in pre-market despite trading near 52-week low, down 46% from peak of $109.50
  • WATCHMAN and electrophysiology segments face slower-than-expected growth; urology division underperforming in key areas
  • CEO Mahoney reaffirmed commitment to innovation and strategic investments to navigate challenges and deliver long-term shareholder value
Last Updated: 22-04-2026, 06:46 pm
Read Full Transcript

Compare BSX to Peers and Sector

Metrics to compare
BSX
Peers
Sector
Relationship
P/E Ratio
25.9x25.9x−0.4x
PEG Ratio
0.350.370.00
Price/Book
3.8x5.2x2.6x
Price / LTM Sales
4.5x3.4x3.2x
Upside (Analyst Target)
35.3%24.9%46.2%
Fair Value Upside
Unlock9.9%7.2%Unlock

Analyst Ratings

32 Buy
1 Hold
0 Sell
Ratings:
33 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 85.94
(+38.45% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Barclays
Buy96.00+54.66%100.00Maintain23-04-2026
JPMorgan
Buy80.00+28.89%100.00Maintain23-04-2026
Oppenheimer
Buy90.00+45.00%100.00Maintain23-04-2026
Wells Fargo
Buy75.00+20.83%94.00Maintain23-04-2026
Nephron
Buy---Upgrade23-04-2026

Earnings

Latest Release
22-04-2026
EPS / Forecast
0.80 / 0.79
Revenue / Forecast
5.2B / 5.17B
EPS Revisions
Last 90 days

BSX Income Statement

FAQ

What Is the Boston Scientific (BSX) Share Price Today?

The Boston Scientific share price today is 62.07 USD.

What is the current Boston Scientific (BSX) share price and day range?

As of 26-04-2026, the Boston Scientific share price is 62.07 USD, with a previous close of 65.69 USD. The share price has ranged from 61.96 to 65.97 USD today, while the 52-week range spans from 59.39 to 109.50 USD.

What Is the Boston Scientific Market Cap?

As of today, Boston Scientific market cap is 92.25B.

What Is the Boston Scientific (BSX) Share Price Target?

The average 12-month share price target for Boston Scientific is 85.94 USD, with a high estimate of 110 USD and a low estimate of 69 USD. 32 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +38.45% Upside potential.

What Is Boston Scientific's Earnings Per Share (TTM)?

The Boston Scientific EPS (TTM) is 2.39.

When Is the Next Boston Scientific Earnings Date?

Boston Scientific will release its next earnings report on 29-07-2026.

From a Technical Analysis Perspective, Is BSX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Boston Scientific Trade On?

Boston Scientific is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Boston Scientific?

The stock symbol for Boston Scientific is "BSX."

How Many Times Has Boston Scientific Stock Split?

Boston Scientific has split 2 times.

How Many Employees Does Boston Scientific Have?

Boston Scientific has 59000 employees.

What Is the BSX Premarket Price?

BSX's last pre-market stock price is 65.06 USD. The pre-market share volume is 15,270.00, and the stock has changed by -0.63 USD, or -0.96%.

What Is the BSX After Hours Price?

BSX's last after hours stock price is 62.10 USD, the stock has changed by 0.03 USD, or 0.05%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.